http://www.pharmalot.com/2011/12/future-for-novartis-hypertension-drug-is-bleak/
“As we see it, there are three obvious options,” write Fernandez in an investor note. “Remove the drug from the market and discontinue all studies for safety reasons; continue to market a potentially hobbled and likely unprofitable franchise, or sell all rights… Since we see little reason to continue marketing a product that could be associated with harm in a large patient population, the fastest option would be removal from the market, while the best outcome likely would be a successful sale of the franchise.”
Hence, no need for a sales force to sell it...
“As we see it, there are three obvious options,” write Fernandez in an investor note. “Remove the drug from the market and discontinue all studies for safety reasons; continue to market a potentially hobbled and likely unprofitable franchise, or sell all rights… Since we see little reason to continue marketing a product that could be associated with harm in a large patient population, the fastest option would be removal from the market, while the best outcome likely would be a successful sale of the franchise.”
Hence, no need for a sales force to sell it...